신경 유전학적 검사 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Neurogenetic Testing Market

The future of the global neurogenetic testing market looks promising with opportunities in the hospital & clinic, research institute, pharmaceutical company, diagnostic laboratory, and academic institution markets. The global neurogenetic testing market is expected to reach an estimated $1980 million by 2035 from $871.5 million in 2027 with a CAGR of 9.8% from 2027 to 2035. The major drivers for this market are the increasing prevalence of neurological genetic disorders, the rising adoption of precision medicine testing, and the growing demand for early disease diagnosis.

• Lucintel forecasts that, within the test type category, predictive testing is expected to witness the highest growth over the forecast period due to more awareness for the need for genetic risk assessment.
• Within the end use category, hospitals & clinics is expected to witness the highest growth over the forecast period due to increment in clinic and hospital-based genetic tests.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to constructing genetic testing infrastructure throughout APAC.

Emerging Trends in Neurogenetic Testing Market

Neurogenetic testing is showing potential in other areas outside of specialist diagnostics. There is growing interest in using neurogenetic testing for broader, more general assessments. In the 2025 to 2027 time frame, various factors are expected to lead to a wider acceptance of neurogenetic testing. These factors include improved interpretation of test results, reduction in the cost of genetic testing, and the availability of evidence to support reimbursement. Lucintel anticipates that in the foreseeable future, neurogenetic testing will be requested predominantly to aid in the diagnosis of rare diseases.

• Whole Genome Sequencing (WGS): As of 2025, it is anticipated that the use of long-read platforms to perform WGS will provide answers for rare diseases.
• Artificial Intelligence (AI): Continuous improvements in computing power, and the increasing role of artificial intelligence (AI) in phenotyping and interpretation of genetic variants will provide neurogenetic testing results more quickly and in a format that is interpretable by non-neurogenetic specialists.
• Early Genomic Screening: The adoption of large-scale genomic screening programs for neonates and children will provide earlier diagnosis of genetic and developmental disorders.
• Therapy-linked Testing: Antisense oligonucleotides and gene replacement therapies are rapidly coming to market. By 2025, the FDA had approved 20 such therapies. Neurogenetic testing will be essential for evaluating eligibility for these treatments. As more therapies come to market, testing will be required to assess the response to treatment and adjust treatment as necessary.
• Reimbursement and Access: The 2025-2027 timeframe is expected to bring increased testing at a lower cost, and payers will expect evidence of the tests' clinical utility. While access will be better due to the aforementioned factors, the variability of specialized counseling and testing across different regions will continue to create inequity in access to the tests.

Neurogenetic testing is expected to expand rapidly in the coming years. While numerous barriers will continue to exist, including patchy implementation of legislation, the focus of the industry will shift to testing and counseling. The largest opportunities will be in therapy selection and other indications in neurology and rare diseases.

Recent Developments in the Neurogenetic Testing Market

Between 2025 and 2027, the market for neurogenetic testing will gain momentum, with larger contributions from pediatrics and neurology, as well as testing for rare diseases. Lucintel anticipates that in the foreseeable future, competition will be greater for excellence in clinical services, rather than for clinical laboratory accreditation. While the cost of genetic testing has come down and is covered by third-party payers in many cases, there are a number of factors that restrict the full realization of the potential of neurogenetic testing.

• Testing Capacity Will Improve: The expected 2025 launch of Illumina's NovaSeq X platform is anticipated to further improve the economics of large scale population neurogenetic testing. Additionally, during the next 3 to 5 years, laboratories will have the capability to generate broader neurogenetic tests and entire genomic sequences.
• Neurological and Pediatric Condition Screening: In 2025, the U.K.'s National Health Service (NHS) continued its effort to implement the Generation Study that provides whole genome sequencing to 100,000 newborns. This initiative and others like it will provide valuable evidence to alter and expand coverage policies in other nations.
• Competitor Changes: Significant changes occurred in the competitive environment during 2025 as large reference laboratories acquired the genomic testing services of smaller competitors. With these changes, larger laboratories will be better positioned to gain and retain payer contracts for neurogenomics testing. Smaller laboratories, however, may be able to retain a competitive edge in neurogenetic testing.
• AI-assisted Interpretation: Predictions about how likely particular genetic variations are to be pathogenic are improving. Genomics companies in 2025 released software to identify variants across the exome and genome. Use of this software is expected to greatly reduce the time required by clinicians to review variants. As with other innovations, the primary barrier to wider adoption of this technology will likely be cost. Further, this technology would likely expand the diagnostic yield of sequencing and, in turn, the clinical utility of genetic testing.
• Pharmacogenomics: There was a similar trend in 2025, in which genomic testing companies and hospital networks entered into collaborations to provide integrated pharmacogenomic testing for neurological conditions. As with the other collaborations, this trend signals that there is an improving body of evidence in support of the economic case for neurogenomics testing.

Variable adoption of neurogenetic testing among health care systems will continue to reflect market forces, including predominance of certain specialties and available reimbursement. Other factors (i.e. variability in the interpretation of genetic findings) will also influence adoption of genetic testing, particularly in the field of neurogenetics. Further, guidance on the clinical utility of genetic testing for certain disorders is likely to shape the role genetics plays in integrating care pathways.

Strategic Growth Opportunities in the Neurogenetic Testing Market

Technological advancements and innovative clinical trials are driving the cost and complexity barriers to neurogenetic testing. Concurrently, growth in the pipeline of neuro-therapies is expected to surge demand for neurogenetic testing. Lucintel believes that, in addition to laboratory services, testing organizations should provide other clinical services such as interpretation, reimbursement, and follow-up of patients, to enhance the commercial and clinical impact of neurogenetic testing.

• Therapy-guiding Testing: The FDA approved the first ever cancer therapy with a genetic-alteration label in March 2025. Other pharmaceutical companies are expected to develop similar therapies in the near-future. As part of their collaborations, sponsoring companies will develop neurogenetic tests to assess eligibility.
• Expanded Newborn Screening: Research shows that next-generation sequencing (NGS) can help detect certain neurological disorders that occur early in life and could help avoid irreversible damages. The UK National Screening Committee (NSC) initiated an investigation to evaluate the evidence for including 221 conditions in their newborn screening program in January 2025.
• Specialty Neurological Testing: In June 2025, the results from a large clinical study were published to help characterize various neurological disorders. As more physicians are made aware of the resources available to assist them, more testing will be requested.
• Decentralized Access Models: When clinical geneticists are unavailable, regional laboratories and tele-genetics providers can help. Only about 2,000 genetic counselors were nationally certified and listed on professional registries in the United States, as of February 2025. Rural and underserved areas can be reached through contracted distributors to collect samples, combined with tele-counseling.
• Longitudinal Data Services: After a patient has been diagnosed, laboratory services can become a continuous, reimbursed service by providing ongoing analysis and interpretation of the variant. As of April 2025, the ClinVar database contained more than 2 million records of genetic variants. Routine reanalysis and reinterpretation of clinical variants will become standard as the database continues to expand and change with new treatments.

Clinical utility, as opposed to the volume of neurogenetic testing, will be the primary driver of market growth. Long-term retention of customers will be determined by the broad scope of services, including molecular genetics, interpretation, counseling, and reimbursed continuous monitoring. Growth will occur as new therapeutic interventions become available for genetically defined conditions. There is some level of risk, including the inability to obtain sufficient patient consent, and uncertain reimbursement. There are also challenges with availability of appropriately trained personnel. These challenges can be addressed through collaboration.

Neurogenetic Testing Market Drivers and Challenges

The neurogenetic testing market is driven by factors including advances in technology and greater public awareness of diseases. Investments in healthcare and markets, as well as changes in legislation, also impact the market. Reductions in the costs of genetic sequencing and growth of genomic data increase access to genetic testing, and, coupled with the increasing demand for personalized medicine, strengthen and reinforced the market. However, challenges such as lack of adequate reimbursement policies, data privacy and security, and inequality in the distribution of specialized personnel and facilities affect market growth. Most positively, the Lucintel report encourages market participants to focus on the value line in an effort to balance the market's needs for sustainability and responsibility.

The factors responsible for driving this market include :

• Recent Advancements in Sequencing Technology: Continuous advancements in next-generation sequencing (NGS) and third-generation sequencing (TGS) technologies along with progress in the fields of bioinformatics have enabled the identification of structural changes and variation in repetitive sequences. Improvement in these technologies is expected to further decrease the cost of whole genome sequencing (WGS). As of January 2025, the cost of a WGS was between US$600 to US$1000. In the coming years, further enhancements in automation and information technology (IT) are likely to decrease the time required for analysis and report, thus improving the diagnostic yield of neurological disorders. The technologies will also allow laboratories to analyze more complex neuro-disorders and larger panels. As of December 2023, more than 60% of clinicians agreed that technology improvements enhanced diagnostic yields without a proportional increase in cost and staffing of laboratories. Improvements in technologies are anticipated to increase diagnostic yields of neuro-disorders and further enhance the competitiveness of the market.
• Growing Need for Molecular Diagnosis: Increased awareness has created a demand for the molecular diagnosis of epilepsy, developmental disorders, hereditary ataxias, and other genetic disorders. Similar to rare diseases, the WHO estimates that 300 million individuals are affected by disorders for which there is no definitive molecular diagnosis. The development of molecular diagnostic tests will fulfill the rising need for diagnosis and have a substantial public health impact. Additionally, molecular diagnostic tests will decrease the diagnostic odyssey that patients and their families are required to endure. The testing will also aid in the determination of the risk status of individuals and families and facilitate reproductive planning.
• Advancing Regulatory and Clinical Practice: Gradual changes to rules and regulations will integrate molecular diagnostic tests into common neurological practice. Positive molecular diagnostic tests will facilitate referrals. The U.S. FDA will continue to promote the approval process for medical devices using molecular and genomic technology. During the next five years, tests will be more closely validated and integrated into clinical practice. These changes will allow health care providers to confidently order the most appropriate molecular diagnostic tests. Integration with other information technology will allow health care providers to efficiently and effortlessly perform all aspects of the testing process including consent, and follow-up.
• Expansion of Genomic Data and Artificial Intelligence: How Artificial Intelligence (AI) and genomic data interact to influence medicine is rapidly evolving. Classifying genetic variants and matching them to the appropriate disease phenotypes is improved by larger, machine learning-enhanced data sets. The All of Us Research Program reported in 2025 that they had sequenced over 245,000 participants and made the data sets available to the research community. In the next 3-5 years, larger data sets are expected to better classify genetic variants and reduce ambiguous results for ethnic and racial minorities.AI is already being used to classify variants and propose diagnostic hypotheses. The broader adoption of personalized medicine and the use of diagnostic tests will require validation of the algorithms to explain their decisions. These algorithms can facilitate and support physicians to perform clinical assessments and integrate diagnostic testing in a clinical setting. The emphasis should be placed on the integration of validated AI algorithms to facilitate clinical judgement rather than using the algorithms to perform clinical assessments.
• Reimbursement and Healthcare Infrastructure: Improved reimbursement policies are expected to improve the availability and use of diagnostic testing. The addition of genetic testing to the Medicare benefits package illustrates the impact that a favorable reimbursement policy can have. The next 3-5 years are expected to bring improved access to molecular diagnostic testing for genetics and other specialty areas throughout the U.S. The same can be said for the extension of tele-health services to provide genetic counseling. The impact of increased diagnostic testing to promote better health and cost savings will rely on data to support that testing provides improved quality of care and lowered overall cost.

The challenges facing this market include:

• Inconsistent Reimbursement: Testing coverage is not the same across different countries, insurers, and types of tests. In 2025, the United States had thousands of private insurance plans with differing requirements for genetic testing. This resulted in variation in pre-authorization and eligibility. In the next 3-5 years, it is expected that, due to lack of adequate reimbursement, laboratory and health-care-related economies would be heavily burdened. The variation would discourage use of broad and comprehensive genetic testing. The testing industry would need to develop research and evidence to influence public policy and court decisions to increase coverage. Standardization of pricing would also help.
• Risks To Privacy and Consent: The data in neurogenetic tests may reveal risks to the tester's family members, and may also suggest the tester's propensity to develop certain conditions in the future. In 2025, the EU's General Data Protection Regulation required service providers to implement additional protections when genetic data was processed. In 2025 and beyond, there is a real threat to the tester's privacy. Unauthorized persons may access the data, and the tests may have uncertain consequences to the tester and family members. Providers of neurogenetic tests must implement adequate safeguards and governance to address these issues.
• Interpretation Capacity and Asymmetrical Access: There are shortages of trained genetic counselors and laboratory scientists, as well as inadequate references. As of July 2025, there were less than 10,000 genetic counselors in the U.S., limiting provision of pre-test counseling and providing patient's complex test results. Inadequate capacity of the workforce in the next 3 to 5 years may result in a backlog of tests, and variability and delays in interpreting results. There also may be variability and delays in providing appropriate treatment. Areas with less infrastructure (e.g. rural areas and developing countries) may be at greater risk, as they may not have access to sequencing and genetics specialize care and support. Variability and differences in the population may result in unknown/unclassified variants due to lack of diversity in reference materials. In the U.S. there is an initiative to improve access to genomic medicine and testing; however, there are barriers including the costs, privacy, and interpretation of results. In the next 3 to 5 years, due to improvement in the technologies and other enablers, the market will experience growth. However, there will be inequitable access to advantages, especially if the focus of innovations is not aligned with overall improvements in healthcare.

List of Neurogenetic Testing Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies neurogenetic testing market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neurogenetic testing market companies profiled in this report include-

• Quest Diagnostics
• Mayo Clinic
• GeneDx
• Illumina
• Labcorp

Neurogenetic Testing Market by Segment

The study includes a forecast for the global neurogenetic testing market by test type, technology, application, end use, and region.

Neurogenetic Testing Market by Test Type [Value ($M) from 2019 to 2035]:

• Predictive Testing
• Carrier Testing
• Diagnostic Testing
• Pharmacogenetic Testing
• Preimplantation Testing

Neurogenetic Testing Market by Technology [Value ($M) from 2019 to 2035]:

• SNP-based Testing
• Whole Exome Sequencing
• Whole Genome Sequencing
• Next-Generation Sequencing
• Microarray Technology

Neurogenetic Testing Market by Application [Value ($M) from 2019 to 2035]:

• Neurological Disorders
• Psychiatric Disorders
• Risk Assessment

Neurogenetic Testing Market by End Use [Value ($M) from 2019 to 2035]:

• Hospitals & Clinics
• Research Institutes
• Pharmaceutical Companies
• Diagnostic Laboratories
• Academic Institutions

Neurogenetic Testing Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Neurogenetic Testing Market

National sequencing programs and regulatory changes will transform neurogenetic testing. Improvements in data and rapid test interpretation will drive adoption from 2025 to 2027, as will reimbursement policies. Lucintel has recently updated its analysis of market trends and competitors.

• United States: Changes in 2024 and 2025 by federal agencies to increase funding and consolidate laboratories will impact neurogenetic testing in the medium-term outlook. Improvements in testing and interpretation will be accompanied by growing databases and artificial intelligence.
• China: A similar outlook is expected in China. BGI, the Chinese genomics company, reported in early 2025 that its gene-sequencing technology was used in more than 100 countries. Continued efforts by the Chinese government to improve the rare-disease diagnosis and treatment infrastructure will improve oncology and genetic testing and reduce the need for imported tests.
• Germany: The genomDE program, supported by Germany's federal health ministry, is utilizing whole genome sequencing in various health centers. Routine sequencing is expected to reveal genetic predispositions for neurological conditions. In April 2025, the ministry confirmed the ongoing development of a national genomic data infrastructure.
• India: The government's investment in genomic infrastructure is facilitating research in indigenous neurogenetics. The GenomeIndia project, launched by the Department of Biotechnology and completed in January 2025, sequenced 10,000 Indians and made the data available to researchers. These resources facilitate the development of genomic tests and aids in interpreting genetic variation.
• Japan: The Japanese government's support of large-scale genomic projects and cancer research facilitates neurogenomics research. In March 2025, the National Cancer Center Japan reported that the number of participants in their biobank-based research increased to 100,000. Standardized processes for consent and research participation are expected to facilitate neurogenomics research.

Features of the Global Neurogenetic Testing Market

• Market Size Estimates: neurogenetic testing market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: neurogenetic testing market size by various segments, such as by test type, technology, application, end use, and region in terms of value ($B).
• Regional Analysis: neurogenetic testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different test types, technologies, applications, end uses, and regions for the neurogenetic testing market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neurogenetic testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the neurogenetic testing market by test type (predictive testing, carrier testing, diagnostic testing, pharmacogenetic testing, and preimplantation testing), technology (snp-based testing, whole exome sequencing, whole genome sequencing, next-generation sequencing, and microarray technology), application (neurological disorders, psychiatric disorders, and risk assessment), end use (hospitals & clinics, research institutes, pharmaceutical companies, diagnostic laboratories, and academic institutions), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Neurogenetic Testing Market by Test Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Test Type
• 4.3 Predictive Testing : Trends and Forecast 2019 to 2035
• 4.4 Carrier Testing : Trends and Forecast 2019 to 2035
• 4.5 Diagnostic Testing : Trends and Forecast 2019 to 2035
• 4.6 Pharmacogenetic Testing : Trends and Forecast 2019 to 2035
• 4.7 Preimplantation Testing : Trends and Forecast 2019 to 2035

5. Global Neurogenetic Testing Market by Technology

• 5.1 Overview
• 5.2 Attractiveness Analysis by Technology
• 5.3 SNP-based Testing : Trends and Forecast 2019 to 2035
• 5.4 Whole Exome Sequencing : Trends and Forecast 2019 to 2035
• 5.5 Whole Genome Sequencing : Trends and Forecast 2019 to 2035
• 5.6 Next-Generation Sequencing : Trends and Forecast 2019 to 2035
• 5.7 Microarray Technology : Trends and Forecast 2019 to 2035

6. Global Neurogenetic Testing Market by Application

• 6.1 Overview
• 6.2 Attractiveness Analysis by Application
• 6.3 Neurological Disorders : Trends and Forecast 2019 to 2035
• 6.4 Psychiatric Disorders : Trends and Forecast 2019 to 2035
• 6.5 Risk Assessment : Trends and Forecast 2019 to 2035

7. Global Neurogenetic Testing Market by End Use

• 7.1 Overview
• 7.2 Attractiveness Analysis by End Use
• 7.3 Hospitals & Clinics : Trends and Forecast 2019 to 2035
• 7.4 Research Institutes : Trends and Forecast 2019 to 2035
• 7.5 Pharmaceutical Companies : Trends and Forecast 2019 to 2035
• 7.6 Diagnostic Laboratories : Trends and Forecast 2019 to 2035
• 7.7 Academic Institutions : Trends and Forecast 2019 to 2035

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Neurogenetic Testing Market by Region

9. North American Neurogenetic Testing Market

• 9.1 Overview
• 9.2 North American Neurogenetic Testing Market by Test Type
• 9.3 North American Neurogenetic Testing Market by End Use
• 9.4 The United States Neurogenetic Testing Market
• 9.5 Canadian Neurogenetic Testing Market
• 9.6 Mexican Neurogenetic Testing Market

10. European Neurogenetic Testing Market

• 10.1 Overview
• 10.2 European Neurogenetic Testing Market by Test Type
• 10.3 European Neurogenetic Testing Market by End Use
• 10.4 German Neurogenetic Testing Market
• 10.5 French Neurogenetic Testing Market
• 10.6 Italian Neurogenetic Testing Market
• 10.7 Spanish Neurogenetic Testing Market
• 10.8 The United Kingdom Neurogenetic Testing Market

11. APAC Neurogenetic Testing Market

• 11.1 Overview
• 11.2 APAC Neurogenetic Testing Market by Test Type
• 11.3 APAC Neurogenetic Testing Market by End Use
• 11.4 Chinese Neurogenetic Testing Market
• 11.5 Indian Neurogenetic Testing Market
• 11.6 Japanese Neurogenetic Testing Market
• 11.7 South Korean Neurogenetic Testing Market
• 11.8 Indonesian Neurogenetic Testing Market

12. ROW Neurogenetic Testing Market

• 12.1 Overview
• 12.2 ROW Neurogenetic Testing Market by Test Type
• 12.3 ROW Neurogenetic Testing Market by End Use
• 12.4 Middle Eastern Neurogenetic Testing Market
• 12.5 South American Neurogenetic Testing Market
• 12.6 African Neurogenetic Testing Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunity by Test Type
  • 14.2.2 Growth Opportunity by Technology
  • 14.2.3 Growth Opportunity by Application
  • 14.2.4 Growth Opportunity by End Use
• 14.3 Emerging Trends in the Global Neurogenetic Testing Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis Overview
• 15.2 Quest Diagnostics
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 Mayo Clinic
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 GeneDx
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 Illumina
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 Labcorp
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.7 Invitae
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.8 MedGenome Labs
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.9 Connecticut Children's
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.10 CENTOGENE
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.11 Victorian Clinical Genetics Services
  • Company Overview
  • Neurogenetic Testing Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us